Multi-omics analysis reveals features improving outcomes and immunotherapy resistance in MSS colorectal cancer - PubMed
5 hours ago
- #immunotherapy
- #bioinformatics
- #colorectal cancer
- Multi-omics analysis identifies features improving outcomes and immunotherapy resistance in MSS colorectal cancer (CRC).
- MSS CRC patients generally have poor prognosis and limited immunotherapy response compared to MSI-H subtype.
- Study integrates 68 single-cell and 3,767 bulk transcriptome samples to identify high immune infiltration in MSS patients.
- Multidimensional features specific to MSS CRC were characterized at cellular and genetic levels.
- 93 AI algorithms were used to construct MLDMPIS (Machine Learning-Derived MSS Prognostic-Immune Signature).
- MLDMPIS showed robust prognostic and immunotherapy response prediction in 1,323 MSS patients and six independent cohorts.
- MLDMPIS outperformed clinical indicators, published prognostic signatures, and immune response models.
- CADM1 was identified as a key molecule linked to MLDMPIS, promoting tumor stemness, proliferation, invasion, and metastasis.